An interventional study of Functional Electrical Stimulation rowing exercise in Spinal Cord Injuries, sponsored by Spaulding Rehabilitation Hospital. Terminated at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Spaulding Rehabilitation Hospital · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital — 3 open to participants now, 8 under way, none of them phase 3. Spinal Cord Injuries · Spaulding Rehabilitation Hospital.
Among the 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital, this one is the 19th largest by enrollment, is one of 3 that started in 2020, is one of 21 with no phase, and was the 15th registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →3 of the 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital are open now, in 1 country. Recruiting first, the newest first:
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–80
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–60
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4
First in 2010; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 24 across the 25 interventional studies. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
Spaulding Rehabilitation Hospital is the lead sponsor of 118 studies on the registry; 27 are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 17 (85%) have results posted.
4 of the studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06514950Spaulding Rehabilitation HospitalYoga Breath Training to Improve Cardiorespiratory Synchrony in Spinal Cord Injury | 2027-01-01 |
| NCT02274116Spaulding Rehabilitation HospitalAcute Intermittent Hypoxia on Leg Function Following Spinal Cord Injury | 2027-08 |
| NCT02323945Spaulding Rehabilitation HospitalEffects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury | 2027-08 |
| NCT06521723Spaulding Rehabilitation HospitalLow Oxygen Therapy to Enhance Walking Recovery After SCI. | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Spinal Cord Injuries by Spaulding Rehabilitation Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Spinal Cord Injury (SCI) leads to alterations in brain structure and function by spinal nerve damage, secondary inflammatory responses, and by the consequences of living with paralysis and neuropathic pain. Physical inactivity due to lower body paralysis rapidly leads to loss of muscle, and risk of heart disease. The leading cause of death after a spinal cord injury is cardiovascular disease, and just a year after injury, those with SCI have a peak exercise capacity half that of the unfit general population.
The good news is that aerobic exercise reduces the risk of chronic metabolic and cardiorespiratory diseases, reduces inflammation and pain, and increases mood and quality of life. Exercise can also reduce brain inflammation, enhance endogenous analgesia, and increases the size of the hippocampus.
The issue is that muscle paralysis in SCI restricts the ability to achieve the levels of exercise that is necessary for broad analgesic, anti-inflammatory and neuroprotective benefits. Arm exercise can have some effects on heart and lung capacity, but the small muscle mass is insufficient to produce more than modest aerobic work. With functional electrical stimulation (FES), leg muscles that are paralyzed can be made to contract, thereby allowing more of the body to be exercised. The full rowing stroke is produced by both the (stimulated) legs and arms, increasing the active muscle mass and resulting in an aerobic work-out that is intensive enough to improve heart, lung, and - maybe - brain function.
In this clinical trial of sub-acute spinal cord injured subjects, the investigators will study how 12 weeks of FES-RT, in comparisons to 12 weeks of wait-list, changes pain, brain structure, endogenous opioid function and brain inflammation.
The investigators will measure changes using positron emission tomography and magnetic resonance imaging. The investigators hypothesize a decrease in pain interference, an increase in hippocampal volume, increased endogenous opioid transmission in the periaqueductal gray, and decreased hippocampus neuroinflammation.
This clinical trial will utilize a randomized, controlled, crossover design. Participants will be randomized to (A) 12 weeks of FES-RT followed by 12 weeks of treatment as usual or (B) 12 weeks of treatment as usual followed by 12 weeks of FES-RT.
Randomization will be computer generated and the study statistician will keep the key to appropriately conceal allocation of treatment until after obtaining baseline measures.
Exercise Intervention:
FES-RT occurs in two distinct steps - an initial strength training step, followed by FES-RT. Those with SCI can require at least two weeks and up to six weeks of strength-training. For the strength training, electrodes are placed over motor points of the quadriceps and hamstrings and intensity of the stimulus is set at the level producing full knee flexion-extension. Training is performed until subjects can complete a flexion extension protocol for 30 min without rest. During this time, the first set of PET-MR data will be obtained.
Subsequently, the FES-RT commences.
Measurements / Assessments Exercise Capacity: Volunteers will perform an incremental exercise test of FES- or arms-only rowing to determine maximal oxygen uptake on a day normally scheduled for regular exercise training. Exercise capacity and aerobic power will be determined from on-line computer-assisted open circuit spirometry. Subjects will row with increasing resistance every 2 min until volitional fatigue. To ensure attainment of maximal exercise capacity, at least 3 of these criteria will be met: 1) O2 consumption plateaus despite increasing workload, 2) respiratory exchange ratio >1.10 at end exercise, 3) age-predicted maximal heart rate is achieved, and 4) perceived exertion is rated at least 16 on the Borg scale of 6-20.
Exercise Volume: The progression of the exercise stimulus across the training program will be assessed from duration, frequency, and intensity derived from heart rate monitored during each exercise bout (i.e., Training Impulses or TRIMPs) as well as the product of average wattage and total duration for each week. TRIMPs are routinely used to quantify the exercise load and is specific to the cardiopulmonary system. The investigators will also calculate exercise load or work as the product of the weekly average of wattage and weekly total of exercise time.
PET-MR imaging
Neuroimaging metrics will be obtained at baseline, after 12 weeks and after 24 weeks. MR-PET scanning will be performed at 3 Tesla, using a Siemens whole-body MRI, whole-body PET camera (Biograph MMR). MRI data will be acquired simultaneously to the PET data.
In response to injury, microglia migrate to the site of injury, and express multiple cell surface proteins, including the translocator protein (18kDa) (TSPO). This conditional expression makes TSPO a prime target for PET imaging (127). There are multiple candidate PET tracers for glial activity , whereof 11C-PBR28 is a sensitive, second generation, high affinity TSPO radioligand suitable for imaging of microglial and astrocytic activation in neuroinflammation in humans. For glial imaging, 11C-PBR28 will be injected intravenously with a slow bolus over a 30s period (130). Dynamic data will be collected over the brain for 90 minutes in list mode, and framed post-collection. The dose will be up to 15mCi, which is equivalent to \~3.7 mSv.
For opioid imaging, 11C-diprenorphine will be injected intravenously, Dynamic data will be collected over the brain for 90 minutes in list mode, and framed post-collection. The dose will be up to 12mCi, which is equivalent to \~2.5 mSv.
For both scans, MR-based attenuation correction maps are created based on the MPRAGE data. For glial imaging, standardized uptake values (SUV), normalized to whole brain PBR28 ligand uptake, will be used. For 11CDiprenorphine, kinetic modeling is carried our using subject specific bilateral occipital cortices as the reference tissues. Nondisplaceable binding potential maps (BPND), representing the relative amount of specifically bound radioligand to that of non-displaceable radioligand, are calculated from the 90 min of dynamic PET data using a simplified reference tissue model with the occipital cortex used as the reference tissue.
A high resolution structural volume will be collected for the purposes of longitudinal structural analyses. All longitudinal data analyses will be done in native space as repeated measurements, thereby avoiding spatial normalization errors typically associated with cohort studies.
A battery of pain, quality of life and psychological well-being questionnaires to the participants on four occasions: immediately after enrollment, at the start of the 12 week wait-list or FES-RT period, at the end of the first arm, and at the end of the cross-over arm (24 weeks).
Conditioned pain modulation: Conditioned pain modulation (CPM) is a psychophysically-based laboratory method to reliably ) evaluate the individual capabilities to inhibit pain in humans. Briefly, CPM is based on the "pain inhibits pain" phenomenon when Stimulus A (test-pain) given together with Stimulus B (conditioning pain) is perceived less painful than when Stimulus A was given alone. Although the literature is not entirely consistent, CPM can be reduced with naltrexone, suggesting at least partial dependence of inhibition on endogenous opioids. CPM will be determined at baseline, 12 weeks and 24 weeks, with the hypothesis that FES-RT will lead to increased CPM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
* SCI at or below neurological level C5 with American Spinal Injury Association grade A, B or C, within 3-24 months after injury.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Exercise training sessions will be performed 3 times per week for 12 weeks. The initial training sessions will include 6 sets of FES-rowing for 5 min at 60% of VO2 peak with a work-to-rest ratio of 2:1. Participants unable to row continuously for 5 min will row for 2-4 min with 30-second breaks incorporated until they achieve sets totaling 30 min. The goal is for each volunteer to achieve an exercise intensity of 70-85% maintained for a continuous 30-40 min performed 3 times each week.
Other: Functional Electrical Stimulation rowing exercise
During the 12-week treatment as usual program, subjects will not participate in FES-rowing.
Full-body aerobic exercise
Change in PROMIS Pain Interference Questionnaire VAS Pain
The Patient-Reported Outcomes Measurement Information System (PROMIS(r)) Pain Interference instrument measure the self-reported consequences of pain on relevant aspects of a person's life and may include the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Pain Interference also incorporates items probing sleep and enjoyment in life. The scale ranges from 6 to 30, with 30 being the highest pain interference.
Time frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
Change in Hippocampal Volume
MRI derived measurement of hippocampus volume in milliliters
Time frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
Change in Hippocampus Glial Activation
11C-PBR28 SUV uptake in the hippocampus
Time frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
Change in PAG Diprenophine Signal
Diprenorphine binds to mu, kappa, and delta receptors. Because opioid receptors are distributed globally throughout the brain, there is no true biological reference region completely devoid of receptors, see PMID: 8051944 for details. Because spinal cord injured patients commonly experience orthostatic hypotension, arterial blood sampling was not done for safey reasons. As a metric of potential within-subject change in opioid receptor binding potential, we caluclated strandardized uptake values (SUV) in the periaqueductal gray as (tissue radioactivity concentration)/(injected dose/patient weigh). This is a unitless metric that reflects a mix of specific binding to opioid receptors (μ, κ, and δ), non-specific tissue binding and free tracer in tissue. A change in Diprenoprhine SUV signal in the PAG is likely to represent, in part, a within-subject change in opoid binding potential. For a detailed discussion, please see PMID: 15275909
Time frame: Change between baseline and after 12 week FES intervention, and after 12 week wait list
| Milestone | FES Rowing | Wait List |
|---|---|---|
| Started | 8 | 5 |
| Completed | 3 | 1 |
| Not completed | 5 | 4 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Technical difficultis with pet/mr | 2 | 2 |
The Patient-Reported Outcomes Measurement Information System (PROMIS(r)) Pain Interference instrument measure the self-reported consequences of pain on relevant aspects of a person's life and may include the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Pain Interference also incorporates items probing sleep and enjoyment in life. The scale ranges from 6 to 30, with 30 being the highest pain interference.
| units on a scale | FES Rowing | Wait List |
|---|---|---|
| Change in PROMIS Pain Interference Questionnaire VAS Pain | 1.9 ± 2.1 | 2.3 ± 2.6 |
MRI derived measurement of hippocampus volume in milliliters
| ml | FES Rowing | Wait List |
|---|---|---|
| Change in Hippocampal Volume | -0.007 ± 0.096 | 0.079 ± 0.096 |
11C-PBR28 SUV uptake in the hippocampus
| Standardized Uptake Value | FES Rowing | Wait List |
|---|---|---|
| Change in Hippocampus Glial Activation | 0.07366122 ± 0.097093 | 0.00872274 ± na |
Diprenorphine binds to mu, kappa, and delta receptors. Because opioid receptors are distributed globally throughout the brain, there is no true biological reference region completely devoid of receptors, see PMID: 8051944 for details. Because spinal cord injured patients commonly experience orthostatic hypotension, arterial blood sampling was not done for safey reasons. As a metric of potential within-subject change in opioid receptor binding potential, we caluclated strandardized uptake values (SUV) in the periaqueductal gray as (tissue radioactivity concentration)/(injected dose/patient weigh). This is a unitless metric that reflects a mix of specific binding to opioid receptors (μ, κ, and δ), non-specific tissue binding and free tracer in tissue. A change in Diprenoprhine SUV signal in the PAG is likely to represent, in part, a within-subject change in opoid binding potential. For a detailed discussion, please see PMID: 15275909
| Standardized Uptake Value | FES Rowing | Wait List |
|---|---|---|
| Change in PAG Diprenophine Signal | -0.065 ± 0.89 | 0.069 ± 1.358 |
Collected over From enrollment until study completion, an average of 1 year per participant. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FES Rowing | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Wait List | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Age, Categorical(Participants) | FES Rowing | Wait List | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 5 | 13 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | FES Rowing | Wait List | Total |
|---|---|---|---|
| Mean | 46 ± 14 | 36 ± 9 | 43 ± 13 |
| Sex: Female, Male(Participants) | FES Rowing | Wait List | Total |
|---|---|---|---|
| Female | 0 | 1 | 1 |
| Male | 8 | 4 | 12 |
| Ethnicity (NIH/OMB)(Participants) | FES Rowing | Wait List | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 7 | 4 | 11 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | FES Rowing | Wait List | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 7 | 3 | 10 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | FES Rowing | Wait List | Total |
|---|---|---|---|
| United States | 8 | 5 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — No HIPAA protects data will be shared. Neuroimaging data may be shared.
Ran from Feb 2020 to primary completion in Nov 2024, 56 months.
Results were first posted in Nov 2026, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spaulding Rehabilitation Hospital →